The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | The future of ADCs in gastric and colorectal cancers
Kristen Ciombor, MD, MSCI, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the potential role antibody-drug conjugates (ADCs) will play in the management of gastrointestinal cancers. The Phase II TROPION-PanTumor03 trial (NCT05489211) of datopotamab deruxtecan, a TROP2-directed ADC, has demonstrated the potential of ADCs in a variety of solid tumors including lung and breast cancers. Other ADCs such as trastuzumab deruxtecan have also shown promising benefits in gastric and colorectal cancers. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
